AstraZeneca and Ionis are planning a US launch next month for Wainua, their treatment for polyneuropathy in life-threatening disease transthyretin-mediated amyloidosis (AT
AstraZeneca have broken out the data they teased last month for transthyretin amyloidosis (ATTR) therapy eplontersen, showing that the drug was effective at slowing down d
AstraZeneca has clearly made the rare disease transthyretin amyloidosis (ATTR) a key component of its rare disease pipeline, licensing a second drug candidate in the space of a couple of mo
South Korea’s Hyundai Bioscience is preparing to start clinical trials of what it hopes could become the first antiviral treatment for dengue fever, a mosquito-borne viral
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.